1. Background {#sec1}
=============

In the setting of a memory clinic, patients with subjective cognitive decline (SCD) are highly relevant [@bib1]. Most of them are "worried well", yet a small proportion of these patients is likely to suffer from preclinical Alzheimer\'s disease (AD) [@bib2], [@bib3]. For both the patient and the clinician, it is important to know who will progress to mild cognitive impairment (MCI) or dementia and who will remain stable [@bib2], [@bib4], [@bib5].

At this point, cerebrospinal fluid (CSF) and magnetic resonance imagining (MRI) markers, and to a lesser extent cognitive tests, are associated with decline in SCD [@bib3], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]. These findings have been translated into the "SCD plus"---criteria that have been developed to identify individuals who are more likely to harbor preclinical AD [@bib2], [@bib14]. Translation to clinical practice is hampered because a set of recommendations for what the diagnostic workup and follow-up for patients with SCD should look like is currently lacking [@bib15], [@bib16].

Clinical decision support systems based on modern machine-learning technologies are being developed to support clinicians to integrate multiple determinants in daily practice [@bib17]. We have previously developed the Disease State Index (DSI) classifier, which is a technology that integrates patient data from multiple modalities to support the clinician in decision-making [@bib18]. In previous studies, we showed that the DSI can distinguish different types of dementia and discriminate between stable and progressive MCI patients [@bib18], [@bib19], [@bib20], [@bib21].

In this study, we aimed to investigate and validate in independent cohorts the prognostic ability of the DSI classifier to identify patients with SCD at risk for progression, by combining and visualizing all available data on baseline characteristics, neuropsychology, CSF biomarkers, and automated MRI features.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

We included 674 patients with SCD with baseline neuropsychology available and a minimal follow-up of 1 year, from three different memory clinic-based cohorts: 354 from the Amsterdam Dementia Cohort (ADC) from the VU Medical Center [@bib22], [@bib23], [@bib24], 51 from Barcelona [@bib25], and 269 from the German Dementia Competence Network (DCN), consisting of nine memory clinics [@bib26], [@bib27]. We used the ADC cohort to develop and internally validate our model and the pooled data of the Barcelona and DCN cohorts to externally validate our model. The study was approved by the local medical ethical committees. All patients provided written informed consent for their clinical data to be used for research purposes.

2.2. Clinical assessment {#sec2.2}
------------------------

All patients went to the memory clinics seeking medical help. At baseline, they received a standardized and multidisciplinary work-up, including medical history and neuropsychological examination. CSF and MRI were performed in a subset of patients. In multidisciplinary consensus meetings, patients were labeled as having SCD when the cognitive complaints could not be confirmed by cognitive testing using a neuropsychological battery and criteria for MCI, dementia, or other neurologic or psychiatric disorder known to cause cognitive complaints were not met.

Annual follow-up took place by routine clinical visits, in which medical and neuropsychological examinations were repeated. As outcome measure, we defined clinical progression as conversion to MCI, AD, or another type of dementia as diagnosed at follow-up. Time to follow-up was defined as time in years from baseline SCD diagnosis to progression or, if stable, time to most recent follow-up date. In the ADC and Barcelona cohort, MCI was diagnosed using Petersen\'s criteria; in addition, all patients fulfilled the core clinical criteria of the NIA-AA for MCI [@bib28], [@bib29]. In DCN, MCI patients met the Jak and Bondi criteria [@bib30]. Patients were diagnosed with probable AD using the criteria of the NINCDS-ADRDA in all centers; all patients also met the core clinical criteria of the NIA-AA for AD dementia [@bib31], [@bib32].

2.3. Neuropsychological tests {#sec2.3}
-----------------------------

Cognitive functions were assessed with a standardized test battery, and we selected those tests that overlapped between the three centers. We used the Mini--Mental State Examination for global cognitive functioning [@bib33]. For measuring executive functioning, we used Trail Making Test A (TMT-A) and Test B (TMT-B), and also for measuring language, category fluency (animals) [@bib34], [@bib35]. For episodic memory, we included the tests that resembled each other most. In ADC, the Rey Auditory Verbal Learning Task (RAVLT) immediate and delayed recall were included [@bib36]. In the Barcelona cohort, the Free and Cued Selective Reminding Test (FSCRT) immediate and delayed total recall were used [@bib37]. In DCN, the Consortium to Establish a Registry for Alzheimer\'s Disease word list immediate and delayed recall were used [@bib38]. To pool the different memory tests, we standardized RAVLT, FSCRT, and Consortium to Establish a Registry for Alzheimer\'s Disease per center to z-scores using group mean (details on distribution can be found in [Supplementary Fig. A1](#appsec1){ref-type="sec"}). Missing data varied per test, details can be found in [Table 1](#tbl1){ref-type="table"}.Table 1Baseline characteristics according to outcome at follow-up for the separate centersVariableADCBarcelonaDCNnStable SCD, n = 291Progressive SCD, n = 63nStable SCD, n = 46Progressive SCD, n = 5nStable SCD, n = 186Progressive SCD, n = 83Demographics Female, n (%)[∗](#tbl1fnlowast){ref-type="table-fn"}354138 (47)26 (41)5134 (74)4 (80)26971 (38)34 (41) Age in years354**61.2 ± 9.669.0 ± 7.1**5164.9 ± 6.470.2 ± 8.3269**64.5 ± 7.868.0 ± 8.4** Education in years35413.3 ± 4.314.0 ± 4.45110.8 ± 4.211.6 ± 4.3269**12.5 ± 2.813.3 ± 3.3** Follow-up in years354**3.4 ± 2.23.8 ± 3.2**513.7 ± 1.82.8 ± 1.8269**2.3 ± 0.91.6 ± 0.7**MCI/AD/non-AD, n42/15/62/2/153/21/9APOE status APOE ε4 carrier, n (%)[∗](#tbl1fnlowast){ref-type="table-fn"}317**92 (35)27 (54)**4910 (22)2 (50)22656 (35)32 (47)Neuropsychology MMSE35128.4 ± 1.728.0 ± 1.551**28.3 ± 1.526.8 ± 1.9**265**28.2 ± 1.627.6 ± 1.8** Memory, immediate recall304**41 ± 937 ± 8**5142 ± 538 ± 6269**20 ± 318 ± 4** Memory, delayed recall303**8 ± 36 ± 3**51**14 ± 613 ± 2**269**7 ± 25 ± 2** TMT-A, seconds31840 ± 1944 ± 145044 ± 1647 ± 18264**42 ± 1551 ± 20** TMT-B, seconds318**97 ± 51113 ± 48**50135 ± 87163 ± 103264**102 ± 41127 ± 52** Category fluency312**22 ± 621 ± 5**5121 ± 517 ± 4269**21 ± 520 ± 5**MRI Hippocampal volume, mL332**7.96 ± 0.837.49 ± 0.81**498.20 ± 0.807.77 ± 1.1293**7.92 ± 0.847.19 ± 1.12** cMTA332**0.37 ± 0.460.54 ± 0.54**490.22 ± 0.430.40 ± 0.5493**0.54 ± 0.531.08 ± 0.86** cGCA3320.75 ± 0.650.87 ± 0.62490.10 ± 0.240.22 ± 0.3693**0.49 ± 0.641.17 ± 0.90** Grading332**0.22 ± 0.190.36 ± 0.22**490.09 ± 0.120.23 ± 0.2293**0.21 ± 0.230.44 ± 0.32**CSF Aβ~42~, pg/mL227**875 ± 235638 ± 279**41771 ± 221637 ± 19487**846 ± 300670 ± 305** Total tau, pg/mL227**266 ± 146456 ± 370**41**333 ± 227645 ± 694**87**286 ± 152454 ± 281** p-tau, pg/mL227**46 ± 1865 ± 34**4155 ± 2883 ± 6587**48 ± 2063 ± 35**[^1][^2][^3][^4][^5]

2.4. MRI {#sec2.4}
--------

In ADC, patients were scanned routinely on a 1.0 T (n = 183), 1.5 T (n = 26), or 3.0 T (n = 123) MRI scanners. Images were acquired on a 3.0 T scanner in Barcelona (n = 49) and on 1.5 T scanners in DCN (n = 93). A set of computed MRI imaging biomarkers were extracted using an image quantification tool (Combinostics Oy, Tampere, Finland, [www.cneuro.com/cmri/](http://www.cneuro.com/cmri/){#intref0010}) [@bib19]. We included four features in the current analysis: hippocampal volume, a computed medial temporal lobe atrophy (cMTA) score, a computed global cortical atrophy (cGCA) score, and region-of-interest (ROI)--based grading. They were derived as follows: first, whole-brain segmentation into 136 structures was performed using multi-atlas segmentation method [@bib39]. From these structures, total (left + right) hippocampal volume was used in the classification. In addition, cMTA score was derived from the volumes of the hippocampus and inferior lateral ventricles [@bib40]. Similarly, cGCA score was estimated using voxel-based morphometry [@bib40]. Finally, the ROI-based grading method measures the similarity of the patient image to patient images from a certain diagnostic group. In practice, an ROI from the patient is represented as a linear combination of the corresponding ROIs from a database of reference images. As each reference image contains also information about the patient\'s diagnostic label, the grading feature is defined as the share of the weights from images with a certain diagnostic label. In this work, we used an ROI centered around the hippocampus [@bib41]. See [Supplementary Fig. A2](#appsec1){ref-type="sec"}, for a schematic presentation of this method. For classification, the volume of the hippocampus was normalized first for head size [@bib42] and then for gender using the LMS method (referring to smooth curve \[L\], mean \[M\], and coefficient of variation \[S\]) [@bib43]. The grading feature was also normalized for gender.

2.5. CSF {#sec2.5}
--------

CSF samples from both ADC (n = 227) and Barcelona (n = 41) were analyzed at the Neurochemistry Laboratory at the Department of Clinical Chemistry of the VUmc, the Netherlands. In DCN (n = 87), samples were analyzed at the laboratory of the University of Erlangen, Germany. All centers measured amyloid-β 1-42 (Aβ~42~), total tau, and tau phosphorylated at threonine 181 (p-tau) with commercially available ELISAs (Innotest; Fujirebio, Ghent, Belgium).

2.6. APOE genotyping {#sec2.6}
--------------------

In ADC (n = 317), the apolipoprotein E (APOE) genotype was determined with the LightCycler APOE mutation detection method (Roche diagnostics GmbH, Mannheim, Germany). In Barcelona (n = 49), the APOE genotype was determined with PCR amplification and Sanger sequencing (ThermoFisher, USA). In DCN (n = 226), leukocyte DNA was isolated with the Qiagen Isolation Kit (Qiagen, Hilden, Germany). Patients were dichotomized into APOE ε4 carriers (heterozygous and homozygous) and noncarriers.

2.7. Disease State Index {#sec2.7}
------------------------

For classifying patients at risk of progression or not, we used a modification of the PredictND tool that was previously developed in the European FP7 project PredictND ([www.predictnd.eu](http://www.predictnd.eu){#intref0015}). The tool is based on the DSI classifier [@bib17]. When presented with a new patient, the DSI estimates the similarity of measurement values from this patient to observed values from reference patients with and without a certain medical condition, in this case similarity to patients with stable SCD and patients progressing to MCI or dementia [@bib17]. Similarity is estimated in the following way: (1) Each measurement value of an individual person is compared with the reference data using a fitness function defined as f(x) = FN(x)/(FN(x)+FP(x)), where FN is the false-negative error rate, and FP is the false-positive error rate in the reference data when using the individual\'s measurement value x as a cutoff value in classification. (2) The "relevance" of each determinant is defined as sensitivity + specificity − 1. (3) Finally, a composite DSI is defined as a weighted average of fitness values: DSI = Σ (relevance ⋅ fitness)/Σ relevance. DSI is a continuous value between zero and one, reflecting how similar an individual is to patients who have previously progressed. A cutoff value of 0.5 is used to classify whether an individual patient is more likely to remain stable (DSI \< 0.5) or progress to MCI or dementia (DSI ≥ 0.5) at follow-up. In addition, we studied whether the performance is improved for a subset of patients with high (DSI \> 0.7 and DSI \> 0.8) or low (DSI \< 0.3 and DSI \< 0.2) DSI values. This could enable detecting patients with very low risk or very high risk of progression for clinical counseling. The classifier also provides a visual representation of how different features contribute to the DSI in a so-called disease state fingerprint (see [Fig. 2](#fig2){ref-type="fig"}, for details). As the DSI combines multiple independent classifiers (fitness functions), there is no need to impute data or exclude cases with incomplete data. More mathematical details can be found in the study by Mattila et al. [@bib17].Fig. 1The visualization of group-wise volume differences between stable subjective cognitive decline (SCD) and progressive SCD groups. The map visualizes the relative volume difference: $\frac{V_{p} - V_{s}}{0.5 \times \left( {V_{p} + V_{s}} \right)}$, where V~p~ and V~s~ are the mean volumes for progressive and stable groups, respectively. Blue indicates the structures on MRI that were larger in the progressive group, and red indicates the structures that were smaller.Fig. 2Examples of DSI fingerprints: patient A and patient C remained stable, and patient B progressed to MCI. The DSI fingerprint combines all data available from one patient and displays it in a visually attractive format to the clinician. The DSI value is presented both numerically and visually with color. The color changes from blue to red when DSI increases from zero (high similarity to the stable group) to one (high similarity to the progressive group). The relevance is visualized by the size of the box. The larger the box, the better the specific marker discriminates the stable and progressive SCD patients. Abbreviations: MMSE, Mini--Mental State Examination; TMT, Trail Making Test; cGCA: computed cortical atrophy score, estimated using gray matter concentration; cMTA, computed medial temporal lobe atrophy score, (left + right)/2, derived from volumes of hippocampus and lateral ventricles; Amyloid β, amyloid-β 1--42; Phosphorylated tau, tau phosphorylated at threonine 181; DSI, Disease State Index.

### 2.7.1. Development and internal validation {#sec2.7.1}

We developed the model on the ADC data and internally validated this model on the same cohort using 10 iterations of three-fold cross-validation. We assessed the different data sources separately (demographics, APOE status, neuropsychology tests, CSF biomarkers, and computed MRI imaging markers) and then combined them, independent of missing data. Owing to the technical differences between scanners, we excluded MRI features from patients scanned with 1.0 T devices (n = 183) from the training set and tested using all field strength and only \>1.0 T. In this way, the classifier is able to better learn the differences between diagnostic groups without the excess variation from the scanner differences (for details, see [Supplementary Table A1](#appsec1){ref-type="sec"}). We used the following performance metrics in the evaluation of the DSI: the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). Although DSI balances the results by default, we also estimated balanced accuracy that is typically defined as mean of sensitivity and specificity. As an outcome measure, we defined progression to MCI or dementia, and we also repeated the analyses including only progression to MCI or dementia due to AD (excluding other dementias).

### 2.7.2. External validation {#sec2.7.2}

For external validation, we tested our developed model on new, unseen cases from pooled Barcelona and DCN data. To understand why the performance decreased with the independent validation cohort, we repeated the analyses by training the model and performing cross-validation with the Barcelona and DCN data, and using the ADC data as a separate validation cohort.

### 2.7.3. Comparison to other machine-learning algorithms {#sec2.7.3}

Earlier studies have performed comprehensive comparisons between the DSI classifier and other machine-learning algorithms [@bib17], [@bib44], [@bib45]. We add on to this by comparing the classifier to Naïve Bayes and Random Forest classifiers. Details can be found in [Appendix](#appsec1){ref-type="sec"}.

2.8. Other statistical analyses {#sec2.8}
-------------------------------

We investigated differences in baseline characteristics in each center according to outcome, using Student\'s t-test and the chi-square test when appropriate, using SPSS, version 22 (IBM, Armonk, NY, USA). *P* \< .05 was considered significant. The DSI analysis was performed using MATLAB toolbox in MATLAB, version R2015b (MathWorks, Natick, MA, USA) [@bib46].

3. Results {#sec3}
==========

3.1. Baseline characteristics {#sec3.1}
-----------------------------

After a mean of 2.9 ± 2.0 years, 151 (22%) patients showed clinical progression to MCI or any type of dementia ([Table 1](#tbl1){ref-type="table"}). Patients who showed progression were older, more frequent APOE ε4 carriers, performed somewhat worse on neuropsychological tests, and had smaller hippocampal volumes and more abnormal CSF biomarkers. Patients in ADC were younger as compared with Barcelona and DCN. Patients in Barcelona were more often female, had less education, and showed less progression as compared with ADC and DCN. Duration of follow-up was longest in Barcelona and shortest in DCN. There were no differences in percentage of APOE ε4 carriers and baseline Mini--Mental State Examination across the centers.

3.2. Development and internal validation of the model {#sec3.2}
-----------------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows performance of the DSI using the different data sources, for progression to MCI or dementia. As single data source, CSF showed highest balanced accuracy, followed by the automatic MRI features. [Fig. 1](#fig1){ref-type="fig"} shows the group-wise volume differences between stable SCD and progressive SCD groups, with the clearest differences observed in the medial temporal region.Table 2Performance of DSI to predict conversion to MCI or any type of dementia in the ADC cohort, for the total cohort and for patients with extreme DSI valuesVariable%Stable SCD, nProgressive SCD, nAUCBalanced accuracySensitivitySpecificityPPVNPVDemographics291630.74 ± 0.0466.0 ± 5.066.0 ± 11.765.9 ± 6.129.7 ± 3.890.1 ± 2.8APOE267500.60 ± 0.0559.7 ± 4.953.9 ± 8.465.5 ± 4.522.7 ± 4.488.4 ± 2.4Neuropsychology290620.69 ± 0.0662.7 ± 4.461.6 ± 10.864.3 ± 5.326.9 ± 3.388.7 ± 2.4CSF194330.77 ± 0.0769.9 ± 5.066.1 ± 11.373.6 ± 6.530.3 ± 5.892.8 ± 2.6MRI (1 T, 1.5 T, 3 T)277550.68 ± 0.0561.4 ± 4.380.1 ± 10.142.8 ± 6.821.8 ± 2.591.9 ± 3.5MRI (\>1 T)123250.73 ± 0.0969.1 ± 7.864.9 ± 15.273.3 ± 7.633.6 ± 9.691.3 ± 4.0Demographics + APOE + Neuropsychology + CSF + MRI (1 T, 1.5 T, 3 T)291630.80 ± 0.0574.0 ± 4.282.9 ± 8.465.1 ± 5.834.2 ± 3.894.7 ± 2.4Demographics + APOE + Neuropsychology + CSF + MRI (\>1 T)291630.81 ± 0.0674.1 ± 5.875.7 ± 11.272.6 ± 4.837.7 ± 5.593.3 ± 2.8DSI \< 0.2 or DSI \> 0.8 Demographics + APOE + Neuropsychology + CSF + MRI (1 T, 1.5 T, 3 T)14 ± 412 ± 55 ± 20.81 ± 0.1083.3 ± 7.498.9 ± 4.267.7 ± 13.659.0 ± 17.499.4 ± 2.3 Demographics + APOE + Neuropsychology + CSF + MRI (\>1 T)21 ± 620 ± 85 ± 20.83 ± 0.1184.1 ± 9.685.4 ± 17.682.8 ± 7.156.2 ± 17.196.3 ± 4.6DSI \< 0.3 or DSI \> 0.7 Demographics + APOE + Neuropsychology + CSF + MRI (1 T, 1.5 T, 3 T)37 ± 634 ± 710 ± 30.84 ± 0.0680.7 ± 6.089.6 ± 11.471.8 ± 9.447.8 ± 10.996.8 ± 3.0 Demographics + APOE + Neuropsychology + CSF + MRI (\>1 T)48 ± 647 ± 79 ± 30.84 ± 0.0984.1 ± 7.384.9 ± 14.283.3 ± 5.550.8 ± 12.997.0 ± 2.6[^6][^7]

When we used all the data sources together, performance improved (balanced accuracy: 74.0 ± 5.5%). The model had high NPV (93.3 ± 2.8), whereas PPV was only modest (37.7 ± 5.5). This indicates that the DSI classifier was most useful to identify patients who remained stable. When we repeated the analyses for progression to MCI or dementia due to AD (excluding other dementias) as an outcome measure, results were comparable ([Supplementary Table A2](#appsec1){ref-type="sec"}).

[Table 2](#tbl2){ref-type="table"} also presents performance of the DSI classifier for subgroups having high or low DSI values, to aid the clinician on how to interpret the DSI values. We observed extreme DSI values, that is, below 0.3 or above 0.7, in 48 ± 6% of the patients. When DSI \< 0.3, NPV was 97.0 ± 2.6, indicating that the probability of progression is very low in this subset and the clinician could reassure these patients with high confidence. For comparison, if NPV is computed for all patients without using any prediction model, it is 82.0 \[291/(291 + 63)\], showing that DSI can clearly help in stratifying patients. When DSI \> 0.7, PPV was not very high, only 50.8 ± 12.9. Although the progression of an individual cannot be predicted accurately even in this subgroup, the risk of conversion is clearly elevated. The risk ratio is 2.8 in this subgroup compared with the whole patient population meaning that the clinician might start applying more rigorous follow-up and lifestyle intervention measures to these patients. This means that for roughly half of SCD patients, the DSI could have practical use to aid in individualized prognosis.

[Fig. 2](#fig2){ref-type="fig"} shows the DSI fingerprints for three example patients to illustrate how the tool integrates and visualizes available data. Patient A is a 60-year-old female, with a DSI of 0.20, meaning the clinician can reassure her with high accuracy. Nearly all the boxes in the fingerprint are blue, which fits with the good outcome in this patient; she remained stable during three years of follow-up. Patient B is a 74-year-old female with a DSI value of 0.83, mainly attributable to her values on MRI and CSF (visible as red boxes). This implies her risk of progression is clearly elevated, and follow-up should be discussed. This patient progressed to MCI after 3 years. Patient C is a 66-year-old female, who remained stable during a follow-up period of 4 years. The fingerprint shows both red and blue boxes, implying that interpretation is inconclusive and a reliable prognosis cannot be made, further illustrated by an inconclusive DSI value of 0.47.

3.3. External validation {#sec3.3}
------------------------

When we externally validated our model by testing it in pooled data of Barcelona and DCN, we found an overall lower performance (balanced accuracy 65.1, NPV 83.7; [Table 3](#tbl3){ref-type="table"}). Balanced accuracy increased to 78.5 in the more extreme DSI values. To evaluate what caused the lower performance on external validation, we also trained the model on pooled data of Barcelona and DCN and tested it in ADC data ([Supplementary Table A3](#appsec1){ref-type="sec"}). Even when we developed the model in Barcelona and DCN cohorts, performance was still better in ADC (balanced accuracy 73.3, NPV 92.4).Table 3External validation: Performance of DSI to predict conversion to MCI or any type of dementia when tested in the pooled data of Barcelona and DCN cohorts, for the total cohort and for patients with extreme valuesVariable%Stable SCD, nProgressive SCD, nAUCBalanced accuracySensitivitySpecificityPPVNPVDemographics232880.6357.861.454.333.878.8APOE203720.5757.447.267.534.078.3Neuropsychology232880.6963.963.664.240.382.3CSF90390.6961.759.064.441.878.4MRI100420.7767.473.861.044.384.7Demographics + APOE + Neuropsychology + CSF + MRI232880.7265.168.262.140.583.7DSI \< 0.2 or DSI \> 0.8 Demographics + APOE + Neuropsychology + CSF + MRI2138300.8178.583.373.771.484.8DSI \< 0.3 or DSI \> 0.7 Demographics + APOE + Neuropsychology + CSF + MRI4594500.7974.276.072.359.485.0[^8][^9]

3.4. Comparison to other machine-learning algorithms {#sec3.4}
----------------------------------------------------

For comparison, other machine-learning algorithms were also tested. The performance of the Naïve Bayes classifier was corresponding to and the Random Forest classifier lower than what was obtained by the DSI classifier ([Supplementary Table A4](#appsec1){ref-type="sec"}).

4. Discussion {#sec4}
=============

In this large memory clinic study, we found that after an average follow-up of almost 3 years, 22% of the individuals with SCD showed clinical progression to MCI or dementia. The DSI classifier combining cognitive test results, automated MRI features, and CSF biomarkers accurately classified 74% of the patients, with especially high NPV. Nearly half of the patients had a clearly positive or negative DSI of \<0.3 or \>0.7, where balanced accuracy was as high as 84%.

Although many individuals with SCD may indeed be "worried well," a minority visits the memory clinic because they actually experience cognitive decline, which the clinician is not yet able to verify. We show that a computer-aided decision tool could support clinicians in identifying that minority of individuals who are at high risk of clinical progression. Moreover, for a larger group of individuals, reassurance can be even more explicit, backed up by negative findings on a combination of diagnostic tests. For daily clinical routine, this could imply a paradigm shift; it is current practice to reassure patients with SCD but not disclose results of their particular diagnostic tests. Our results provide support for the notion, however, that we approach an era of personalized medicine, where individuals\' results on diagnostic tests can be used to obtain individualized predictions. Our classifier may aid in providing prognosis or decide to follow up individuals at increased risk for progression. On further scrutinizing the data, we observed that performance was particularly good for roughly half of the population, with a high or low DSI (\<0.3 or \>0.7), while prognostic performance was suboptimal for those with a medium DSI (0.4-0.6) (data not shown). Yet, overall NPV was very high, reaching up to 97.0 for the cases with DSI \< 0.3. This implies that patients with a DSI \< 0.3 can be reassured and do not need follow-up. For patients with a DSI \> 0.7, a certain prognosis cannot be made, but the risk of clinical progression is clearly elevated and follow-up is warranted. The fingerprint could further aid in this interpretation by visualizing how each of the determinants contributed to the prognosis. Of note, in the present study, we focused on patients who present to a memory clinic with the clinical question whether they have an underlying neurodegenerative disease. In further work, tools like this could also be used for screening patients at risk in the general population, for example, by using blood-based biomarkers [@bib47].

The overall balanced accuracy of the DSI was highest when we combined all different data sources. The discriminative effect of MRI and CSF biomarkers are in line with the additive model, indicating patients with SCD at risk of progression already have more AD-like biomarkers at baseline [@bib48]. Also, neuropsychological assessment at baseline improved the performance of the DSI. It is conceivable that even within normal boundaries, a slight decline in cognitive performance is associated with progression, which is particularly appreciated when analyzed together with data from other sources. The classifier also provided fully automatically computed MRI features enabling the clinician to extract more information from the images than when using visual interpretation only [@bib19].

The strength of this study was the large size of the cohort in which the model was developed, and the availability of two independent cohorts for external validation. All patients underwent thorough examination and were only included if cognitive complaints could not be confirmed by cognitive testing. We used data that were typical of memory clinics, varied and incomplete. Because we aimed to develop a tool that should be able to support clinicians in daily practice, it is essential the tool can deal with missing data.

However, several potential limitations also need to be discussed. In general, when developing prediction models based on classifiers, comparing training and testing results can be challenging for several reasons. In this study we trained the tool on the ADC data and found that on validation in the Barcelona and DCN data, performance was less optimal. This might indicate that generalizability is limited. When we trained the tool in the Barcelona and DCN data and then performed external validation in ADC, we still found that performance was better in ADC than in the Barcelona and DCN data. This suggests that not the model itself hampers generalizability, but the lower performance is caused by heterogeneity in cohorts. Overall, the following sources can affect generalizability of prediction models: (1) patients in different memory clinics are different (i.e., both referral and definition of SCD), (2) heterogeneity in outcome, (3) patient measurements are done in different ways, and (4) prediction models are not able to generalize. In the field of SCD, heterogeneity between cohorts is an important hurdle [@bib2], [@bib5], [@bib49]. The field is acknowledging this and working toward more harmonization of research efforts. Nonetheless, it is of the utmost importance to actually perform studies on multiple data sets, both to get to know the differences and how this influences results, and to start harmonizing and bridging data. In this study, we feel there are several important cohort differences: first, patients showed substantial baseline differences between the three memory clinic cohorts. We found differences regarding progression rates and definition of progression; ADC and Barcelona used the Petersen criteria for MCI, whereas DCN used the Jak-Bondi criteria for MCI [@bib28], [@bib30]. Also those who remained stable in Barcelona and DCN were older than those in ADC. Second, although follow-up duration in VUmc was longer, more patients showed progression in Barcelona + DCN. Third, although all patients underwent a harmonized work-up, the work-up differed between the centers. We tried to eliminate these differences as much as possible. For the neuropsychology tests, we selected tests that overlapped or resembled each other. Also, CSF analyses of ADC, DCN, and Barcelona were performed in the two laboratories, as part of the Euro-SCD collaboration, minimizing, but not excluding, interlaboratory variability. MRI scans were acquired on systems with different field strengths, yet the automatic analyses of these scans were all performed by the same software [@bib19]. However, 1.0 T images have worse gray matter--white matter contrast than 1.5 T and 3.0 T images. Consequently, we decided to use only 1.5 T and 3.0 T images in training to have a robust classifier and then reported the results separately for different field strengths to demonstrate the differences between 1.0 T and \>1.0 T images with roughly similar performance. In this study, we did not perform feature selection and choose a set of features maximizing prediction accuracy. We included diagnostics tests and features that are either familiar to clinicians or which we found to be good features in other studies. Had we used an optimal set of features, this would probably increase the performance of our model, at the risk of overfitting.

In conclusion, this study shows that it is feasible to extract and combine information from routine diagnostic tests into a measure that can be used within a clinical decision support system, supporting clinicians to identify individuals at risk of progression who need follow-up and individuals who are likely to remain stable and can be reassured and discharged. This implies that it is possible to think about a personalized medicine approach, also in patients with SCD. Recent research has shown that patients would like to be actively involved in decisions about prognostic testing, but they feel they often lack important information on the implication of the tests [@bib15], [@bib50]. Tools such as the DSI classifier can provide a first step in taking personalized medicine in SCD to a next level.Research in Context1.Systematic review: An increasing number of studies focus on biomarkers that can help identifying patients with subjective cognitive decline (SCD) at risk of progression. Translation to clinical practice is hampered because it remains unclear what the diagnostic workup and follow-up for SCD should look like and what results should be disclosed in daily practice. We cited relevant citations.2.Interpretation: We used a clinical decision support system to identify patients with SCD at risk for progression. Clinical decision support systems can weigh and combine different diagnostic tests; this multivariate model showed especially a high negative predictive value, meaning the classifier identified patients who will remain stable and can thus be reassured.3.Future directions: Clinical decision support systems could be useful to aid clinicians in interpreting diagnostic test results and discuss results of these tests with patients with SCD. To take diagnosis and prognosis in SCD to the next level, further knowledge on shared decision-making in SCD is needed.
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[^1]: Abbreviations: SCD, subjective cognitive decline; ADC, Amsterdam Dementia Cohort; DCN, Dementia Competence Network; AD, dementia due to Alzheimer\'s disease; FTD, frontotemporal dementia; VaD, vascular dementia; DLB, Lewy body dementia; MMSE, Mini--Mental State Examination; RAVLT, Rey Auditory Verbal Learning Task; FSCRT, Free and Cued Selective Reminding Test; CERAD, Consortium to Establish a Registry for Alzheimer\'s Disease; TMT, Trail Making Test; cGCA, computed cortical atrophy score, estimated using gray matter concentration; cMTA, computed medial temporal lobe atrophy score, (left + right)/2, derived from volumes of hippocampus and lateral ventricles; Aβ~42~, amyloid-β 1-42; p-tau, tau phosphorylated at threonine 181.

[^2]: NOTE. Follow-up in years: time to conversion to MCI/dementia or follow-up time for nonconverters. Non-AD cases consisted of (1) ADC: 3 FTD and 3 VaD; (2) Barcelona: 1 DLB; and (3) DCN: 1 FTD, 1 VaD, 3 DLB, and 4 nonspecified dementia.

[^3]: NOTE. Memory, immediate recall: data on immediate recall using RAVLT (ADC), FSCRT (Barcelona), and CERAD (DCN); memory, delayed recall: data on delayed recall using RAVLT (ADC), FSCRT (Barcelona), and CERAD (DCN); hippocampal volume: left plus right hippocampus (in mL), normalized for head size and gender; grading: computed using a region of interest around the hippocampus, describing the intensity similarity of test image and training set images.

[^4]: NOTE. Raw data are presented as mean ± SD or n (%). Group differences per center according to outcomes were calculated using Student\'s t-test for continuous variables. Bold represents *P* values \< .05.

[^5]: For categorical variables, the chi-square test was used.

[^6]: Abbreviations: AUC, area under the receiver operating characteristic curve; SCD, subjective cognitive decline; PPV, positive predictive value; NPV, negative predictive value; APOE, apolipoprotein E; DSI, Disease State Index.

[^7]: NOTE. For the extreme DSI values, n: number of patients in a cross-validation fold having the DSI value in the given range; %: percentage of patients in a test set (n = 118) of a cross-validation fold having the DSI value in the given range. Values are presented as mean ± standard deviation over 10 iterations of three-fold cross-validation.

[^8]: Abbreviations: AUC: area under the receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value; APOE, apolipoprotein E; DSI, Disease State Index; SCD, subjective cognitive decline.

[^9]: NOTE. For the extreme DSI values, n: number of patients having the DSI value in the given range; %: percentage of patients having the DSI value in the given range. Values are presented as mean.
